Member Info for The.Italian

i haven't seen the interview as i do not wish to subscribe to spotify.presumably no one has any positive comments on it,but just wondering why bother to do one now if nothing to say.do quite like the irony though of doing it on spotify.

so booth you are suggesting that perrigo made a conscious decision not to seek to licence med 2005,a product which had failed p111 and not to seek to licence med 3000 ,a product which at the time was undergoing approval and did not receive its ce mark until april this year. you seek to suggest that this reflects a poor opinion of med 3000 when obviously there is no such connection. seems a very muddled and biased thouth process to me.incidentally,for the record i am not suggesting that perrigo have, or will have, any interest in med 3000.i have no idea if they will and frankly neither do you.

absolute gibberish!

interesting appointment.

i am of course fully aware of these statements and see nothing in them to cause me to alter my view. as always i will leave it to others to form their own views.

well i don't know how others will feel ,but personally looking at all those health warnings on the stendra offering makes me want to run a mile!.one of the plus points for med 3000 is that it can be used by those contraindicated for other treatments.

akane this is an old trope, which booth has resurrected in his relentless efforts to destroy any faith in the product. all perfectly understandable fora lth who, as he assures us,is not shorting etc! whilst i personally don't give a toss what his position is (my take would be that it is personal) i think it is impossible to deny that his continued obloquy against the company has had some impact. as i have said previously great care is needed in dissecting has posts in order to form a balanced view of the prospects are.

morning bignose.agree with that.i missed "gratuitous"on first glance.clearly nothing in it for us at the moment.odd about vxr as i think the ASX was open today.

https://finance.yahoo.com/news/deep-longevity-launches-longevity-medicine-073000188.html just to show additional coverage

http://www.endurancerp.com/ICMServlet/download/14-2512-4051/e[Press%20Release]%20Deep%20Longevity%20Launches%20Longevity%20Medicine%20Course%20for%20Physicians.pdf on the news site.not had a chance to read it properly yet and not suggesting there is any money in it,but of minor interest.see venturex was up 11% plus yesterday.can't seem to get today's figure for some reason.

they are coming through now generally.

there are no RNSs posted on lse as yet.

interesting snd compelling view,robidicus. clearly it i.e. essential, if naps is to succeed in its objective of capturing an increased streaming market share, that they have an app which will attracts users from other sites or lead new users to choose naps over alternatives,or both. clearly it is essential that the app is of the highest possible quality and if that takes longer than some would like then hopefully that will prove a price worth paying.

worth checking the FDA news website just after 9.30 pm(4.30 ET) as they do announce news at that time also.

yes in fairness the regulatory regimes for approval are really very exacting,so it's no surprise that so many end in failure. im very much scaled back now in fum,having for once done fairly well (luck again) so fairly relaxed there. that said i do have a reasonable holding in polarean (POLX), which is scheduled for fda decision tomorrow as a drug/decice. may not actually hear until wednesda,y but it's a bit tense.apologies for off topic hoping now for news soon re fda here.

morning bignose.certainly looks that way.yes very fortunate timing for the disposal(ha ha ).so the wait goes on....and on....and on!

afternoon bignose.let us hope so.it really is quite frustrating.

and so our state of nescience continues! sorry just posting out of frustration, as I've no idea what's going on.no news at all.normally I'm very patient and in the last year or so have managed to turn around a couple of fairly dire investment situations just by being patient (luck helps also as always) but this for some reason is getting to me. perhaps they simply intend to update the market when they have details of next steps re trial and are taking the results submission as read on the basis of the previous announcement, but it would be good to know.

croydon i have no idea what will happen,but I'm not expecting any substantial positive movement until we have some tangible news of the app's progress.i am expecting N&G to convert most, if not all, of the remaining 2m,but thats just what i expect.no firm basis for saying it.need to remember their current s/p average is about 1.48p ,so they are underwater, at least when viewed on a simple level.again just a personal view,but i think there is zero chance of matchett going.i also think that expectations of a nasdaq listing are a little premature.it may be matchett's aim (i suspect it has always been his aim, but would never have been possible without a significant revenue stream, hence his, in effect, buying nap's revenue) but it will take much longer than some may be hoping (again just a personal view and doubtless there will be other views on this aspect). no price predictions from me, but i continue to hold.

interesting to see fda today granted approval to siemens's NAEOTUM Alpha. "underscores fad's efforts to encourage innovation in areas of....diagnostic progress". not directly relevant but interestinghttps://www.fda.gov/news-events/press-announcements/fda-clears-first-major-imaging-device-advancement-computed-tomography-nearly-decade